WO2004087102A3 - A process for preparing a pharmaceutical active ingredient with high specific surface area - Google Patents

A process for preparing a pharmaceutical active ingredient with high specific surface area Download PDF

Info

Publication number
WO2004087102A3
WO2004087102A3 PCT/US2004/009447 US2004009447W WO2004087102A3 WO 2004087102 A3 WO2004087102 A3 WO 2004087102A3 US 2004009447 W US2004009447 W US 2004009447W WO 2004087102 A3 WO2004087102 A3 WO 2004087102A3
Authority
WO
WIPO (PCT)
Prior art keywords
surface area
specific surface
high specific
preparing
active ingredient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/009447
Other languages
French (fr)
Other versions
WO2004087102A2 (en
Inventor
Guy Samburski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Teva Pharmaceuticals USA Inc
Original Assignee
Teva Pharmaceutical Industries Ltd
Teva Pharmaceuticals USA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd, Teva Pharmaceuticals USA Inc filed Critical Teva Pharmaceutical Industries Ltd
Priority to DE04758472T priority Critical patent/DE04758472T1/en
Priority to CA002519779A priority patent/CA2519779A1/en
Priority to EP04758472A priority patent/EP1511470A2/en
Publication of WO2004087102A2 publication Critical patent/WO2004087102A2/en
Publication of WO2004087102A3 publication Critical patent/WO2004087102A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Provided is a process for micronization of active pharmaceutical ingredients to provide active pharmaceutical ingredients with a high specific surface area.
PCT/US2004/009447 2003-03-26 2004-03-25 A process for preparing a pharmaceutical active ingredient with high specific surface area Ceased WO2004087102A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
DE04758472T DE04758472T1 (en) 2003-03-26 2004-03-25 PROCESS FOR PREPARING A PHARMACEUTICAL ACTIVE COMPOUND WITH A HIGHLY SPECIFIC SURFACE
CA002519779A CA2519779A1 (en) 2003-03-26 2004-03-25 A process for preparing a pharmaceutical active ingredient with high specific surface area
EP04758472A EP1511470A2 (en) 2003-03-26 2004-03-25 A process for preparing a pharmaceutical active ingredient with high specific surface area

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45808303P 2003-03-26 2003-03-26
US60/458,083 2003-03-26

Publications (2)

Publication Number Publication Date
WO2004087102A2 WO2004087102A2 (en) 2004-10-14
WO2004087102A3 true WO2004087102A3 (en) 2004-12-09

Family

ID=33131747

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/009447 Ceased WO2004087102A2 (en) 2003-03-26 2004-03-25 A process for preparing a pharmaceutical active ingredient with high specific surface area

Country Status (6)

Country Link
US (1) US20040247689A1 (en)
EP (1) EP1511470A2 (en)
CA (1) CA2519779A1 (en)
DE (1) DE04758472T1 (en)
ES (1) ES2233227T1 (en)
WO (1) WO2004087102A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002068398A1 (en) * 2001-02-27 2002-09-06 Teva Pharmaceutical Industries Ltd. New crystal forms of lamotrigine and processes for their preparations
WO2003090693A2 (en) * 2002-04-23 2003-11-06 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing lamotrigine particles of defined morphology
GB0617171D0 (en) * 2006-08-31 2006-10-11 Generics Uk Ltd Novel compositions and methods
EP2158913A1 (en) * 2008-08-25 2010-03-03 Ratiopharm GmbH Pharmaceutical composition comprising N-[3-chhloro-4-[(3-fluorophenyl)methoxy]phenyl]6-(5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine
US20220265566A1 (en) * 2018-10-18 2022-08-25 Tulex Pharmaceuticals Inc. Atovaquone nanoparticulate compositions
CN109172534B (en) * 2018-10-23 2020-08-07 迪沙药业集团有限公司 Nifedipine sustained-release tablet composition
CN109568283B (en) * 2018-12-28 2020-08-28 地奥集团成都药业股份有限公司 Nifedipine sustained release tablet and preparation method thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH670201A5 (en) * 1985-06-03 1989-05-31 Sandoz Ag Solid dispersions of water-insol. drugs - comprising coherent crystals of drug in water-soluble matrix
EP0680752A2 (en) * 1991-04-11 1995-11-08 Astra Aktiebolag Conditioned water soluble substances
WO1999048517A1 (en) * 1998-03-25 1999-09-30 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Pharmaceutical compositions for prolonged peptide release and preparation method
US6475507B1 (en) * 1997-04-18 2002-11-05 Ipsen Pharma Biotech Sustained release compositions and the process for their preparation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1579818A (en) * 1977-06-07 1980-11-26 Yamanouchi Pharma Co Ltd Nifedipine-containing solid preparation composition
DE3270785D1 (en) * 1981-10-29 1986-05-28 Bayer Ag Process for preparing solid fast-releasing drug formulations of dihydropyridines
JPS59101423A (en) * 1982-12-02 1984-06-12 Takada Seiyaku Kk Novel solid pharmaceutical preparation of nifedipine
IT1187751B (en) * 1985-10-15 1987-12-23 Eurand Spa PROCEDURE FOR THE PREPARATION OF SOLID FORMULATIONS OF NIFEDIPINE WITH HIGH BIO AVAILABILITY AND WITH PROLONGED EFFECT AND FORMULATIONS SO OBTAINED
EP0272336B1 (en) * 1986-12-18 1991-10-23 Kurt H. Prof. Dr. Bauer Nifidipine concentrate stabilized against the influence of light, and method for its preparation
NO883326L (en) * 1987-08-11 1989-02-13 Bayer Ag DHP-retard-COOK.
US4954346A (en) * 1988-06-08 1990-09-04 Ciba-Geigy Corporation Orally administrable nifedipine solution in a solid light resistant dosage form
US20040115134A1 (en) * 1999-06-22 2004-06-17 Elan Pharma International Ltd. Novel nifedipine compositions

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH670201A5 (en) * 1985-06-03 1989-05-31 Sandoz Ag Solid dispersions of water-insol. drugs - comprising coherent crystals of drug in water-soluble matrix
EP0680752A2 (en) * 1991-04-11 1995-11-08 Astra Aktiebolag Conditioned water soluble substances
US6475507B1 (en) * 1997-04-18 2002-11-05 Ipsen Pharma Biotech Sustained release compositions and the process for their preparation
WO1999048517A1 (en) * 1998-03-25 1999-09-30 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Pharmaceutical compositions for prolonged peptide release and preparation method

Also Published As

Publication number Publication date
EP1511470A2 (en) 2005-03-09
CA2519779A1 (en) 2004-10-14
US20040247689A1 (en) 2004-12-09
ES2233227T1 (en) 2005-06-16
WO2004087102A2 (en) 2004-10-14
DE04758472T1 (en) 2005-06-23

Similar Documents

Publication Publication Date Title
WO2003082853A8 (en) New compounds
WO2005089718A3 (en) Pharmaceutical compositions
WO2004055006A8 (en) Novel compounds having selective inhibiting effect at gsk3
WO2005065185A3 (en) Temperature-stable formulations, and methods of development thereof
AU2003244632A1 (en) Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
WO2004012700A3 (en) Dosage form comprising high dose high soluble active ingredient as modified release and low dose active ingredient as immediate release
EP1728791A4 (en) Composition for solid pharmaceutical preparation of solifenacin or salt thereof
PL367447A1 (en) Novel 2h-pyridazine-3-one derivatives, pharmaceutical compositions containing the same and a process for the preparation of the active ingredient
AU2003287699A1 (en) Production of pharmaceutically active proteins in sprouted seedlings
AU2003244649A1 (en) Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
AU2003282782A1 (en) Pharmaceutically active lipid based formulation of sn38
WO2002087546A3 (en) Method for manufacturing a low dose pharmaceutical composition
WO2004032826A3 (en) Process for preparing tannate tablet capsule or other solid dosage forms
IL179719A0 (en) Process for preparation of amorphous form of drug
WO2005097076A3 (en) Low dose pharmaceutical products
WO2005107721A3 (en) Pharmaceutical dosage form comprising pellets as well as its manufacturing process
WO2001079174A8 (en) A pyridine-1-oxide derivative, and process for its transformation into pharmaceutically effective compounds
MXPA02012889A (en) 4-alkoxy cyclohexane-1 amino carboxylic acid esters and method for the production thereof.
WO2007083188A3 (en) Improved process for the preparation of an optically active 5h-pyrrolo [3,4-b] pyrazine derivative
WO2004087102A3 (en) A process for preparing a pharmaceutical active ingredient with high specific surface area
WO2004071156A3 (en) Use of edible acid in fast-dispersing pharmaceutical solid dosage forms
WO2006061700A3 (en) Rapid disintegrating taste masked compositions and a process for its preparations
AU2003302188A1 (en) Method of obtaining a soothing active ingredient, active ingredient and compositions obtained
HUP0600084A2 (en) Pharmaceutical compositions containing ascorbic acid derivatives, methods of production of the active ingredient
AP2002002679A0 (en) Novel polymorph V of torasemide.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2004758472

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWP Wipo information: published in national office

Ref document number: 2004758472

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2519779

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 170947

Country of ref document: IL

Ref document number: 4206/DELNP/2005

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2006509396

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 1020057017924

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1020057017924

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 2004758472

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: JP